



Alpa Laboratories Ltd.

33/2, Pigdamber A.B. Road - 453 446 Distt. Indore - (M.P.) India

Phone No. : +91-731- 429 4567 Fax No. : +91-731- 429 4444

Email : mail@alpalabs.com

CIN L85195MP1988PLC004446

Date: -29th May, 2017

**To,
Listing Department,
BSE Limited.
Rotunda Building, P J Towers
Dalal Street, Fort,
Mumbai – 400 001**

**To,
Listing Department,
National Stock Exchange of India Limited.
'Exchange Plaza', C-1, Block G,
Bandra - Kurla Complex,
Bandra (E), Mumbai – 400 051**

Subject: Outcome of Board Meeting under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Reference :- Scrip Code: 532878 ; Scrip Code: ALPA ; ISIN: INE385I01010

Dear Sir/ Madam,

This is to inform you that pursuant to provisions of Regulation 30 & 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the meeting of the Board of Directors of the Company was held today that is on **Monday, 29th May, 2017** at registered office of the Company situated at 33/2, A.B Road, Pigdamber Rao, Indore, Madhya Pradesh has approved the following matter:

1. Approval of Standalone & Consolidated Audited Financial Results of the Company for quarter and year ended 31st March, 2017 .

The Board meeting commenced at 3.00 P.M and concluded at 9.50 P.M.

Please find enclosed herewith the copy of approved **Standalone & Consolidated Audited Financial Results of the Company for quarter and year ended ended 31st March, 2017.**

Kindly take same for your records and oblige.

Thanking you,

Yours Faithfully

For Alpa Laboratories Limited

Mahesh Chawla

MS Chawla

Director

Encl: a/a



Particulars	Standalone Results					Consolidated Results	
	Quarter Ended			Year Ended		Year Ended	
	Mar-17	Dec-16	Mar-16	Mar 2017	Mar 2016	Mar 2017	Mar 2016
			Audited		Audited		
(a) Net sales/income from operations (Net of Excise duty)	2088.84	1684.26	1966.50	6477.23	5063.25	6484.30	5072.05
(b) Other operating income	21.09	24.03	27.81	83.88	286.96	83.88	286.96
1. Total income from operations (net) (a+b)	2109.94	1708.29	1994.31	6561.12	5,350.21	6,568.18	5,359.00
(c) Cost of materials consumed	1054.34	1065.91	1403.93	3807.05	3186.14	3807.11	3186.14
(d) Purchases of stock-in-trade	-	-	-	-	-	-	-
(e) Changes in inventories of fin. goods, stock-in-pro. &	282.24	-62.70	-64.95	52.94	-398.32	52.94	-398.32
(f) Employee benefits expense	268.37	218.82	206.30	863.67	717.45	869.07	720.16
(g) Depreciation and amortization expense	20.69	18.37	22.10	76.08	83.09	480.58	83.09
(h) Other expenses	398.28	302.62	356.96	1126.91	1163.35	1128.09	1316.36
2. Total expenses (c+d+e+f+g+h)	2023.92	1543.02	1924.34	5926.64	4751.71	6337.79	4907.43
3. Profit/ Loss(-) from operations before other income and finance costs and exceptional items (1-2)	86.02	165.27	69.97	634.47	598.50	230.40	451.57
4. Other income	223.62	186.23	193.91	613.05	609.22	538.16	616.79
5. Profit/ Loss(-) from ordinary activities before finance costs and exceptional items (3+4)	309.64	351.50	263.88	1247.53	1207.72	768.56	1068.36
6. Finance costs	27.19	36.20	65.33	170.95	144.62	170.95	144.62
7. Profit/ Loss(-) from ordinary activities after finance cost but before exceptional items (5-6)	282.46	315.30	198.55	1076.58	1063.10	597.61	923.74
8. Exceptional items	-	-	-	211.53	-	211.53	-
9. Net Profit/ Loss(-) from ordinary activities before tax (7+/-8)	282.46	315.30	198.55	865.05	1063.10	386.08	923.74
10. Tax expense	293.00	-	289.14	293.00	289.14	293.00	289.14
11. Net Profit/ Loss(-) from ordinary activities after tax (9-10)	-10.55	315.30	-90.59	572.05	773.96	93.08	634.60
12. loss from extraordinary activities	-	-	-	-	-	-	-
13. Net Profit & Loss after tax and Extraordinary Items (11+/-12)	-10.55	315.30	-90.59	572.05	773.96	93.08	634.60
14. Share of Profit (Loss) of Associates	-	-	-	-	-	-	-
15. Minority Interest (For Consolidated Result Only)	NA	NA	NA	NA	NA	-	0.00
16. Net Profit & loss After Minority Interest and share of profit/ loss of associates (13+14+15)	-10.55	315.30	-90.59	572.05	773.96	93.08	634.60
17. Paid-up equity share capital (Face Value `10 Each)	2104.06	2104.06	2104.06	2104.06	2104.06	2104.06	2104.06
18. Reserves excluding Revaluation Reserves as per bal. sheet of prev. year	-	-	-	7,897.96	7325.91	7329.55	7186.47
19 i Basic and Diluted Earnings per share before extraordinary items ` (not annualized)	-0.05	1.50	-0.43	2.72	3.68	0.44	3.02
20ii Basic and Diluted Earnings per share after extraordinary items ` (not annualized)	-0.05	1.50	-0.43	2.72	3.68	0.44	3.02

1. In 2nd quarter, an additional expense of ` 2.12 cr. (Include in other expense) has been made as a consequence of settlement of arbitration & dispute with Ranbaxy (Sun Pharmaceutical Industries Limited)

2. The above results have been subjected to Limited Review by the Statutory Auditors, reviewed by Board Audit Committee and have been approved by the Board of Directors at its meeting today.

3. The Company is operating in the single segment of Drugs & Chemicals.

4. The Provision for Tax may not have been made for the partial/ unaudited periods.

5. The Figures of Previous Year/ Periods may have been regrouped/ reclassified wherever necessary.



(Handwritten signature)

Annexure IX – Statement of Assets & Liabilities	Standalone		Consolidated	
	Mar 2017	Mar 2016	Mar 2017	Mar 2016
	Audited	Audited	Audited	Audited
Particulars	2104.06	2,104.06	2104.06	2,104.06
(b) Reserves and surplus	7897.96	7,325.91	7329.55	7,186.47
A1. Sub-total - Shareholders' funds (a+b)	10002.02	9429.97	9433.61	9290.53
(c) Long-term borrowings	47.20	-	47.20	-
(d) Deferred tax liabilities (net)	-	-	-	-
(e) Other long-term liabilities	62.77	60.42	62.77	60.42
A2. Sub-total - Non-current liabilities (c+d+e)	109.97	60.42	109.97	60.42
(f) Short-term borrowings	919.19	2,422.89	919.19	2,423.09
(g) Trade payables	1372.26	1,862.27	1372.26	1,862.35
(h) Other current liabilities	389.08	475.65	407.56	572.53
(i) Short-term provisions	442.36	253.37	442.53	463.63
A3. Sub-total - Current liabilities (f+g+h+i)	3122.89	5014.18	3141.54	5321.60
TOTAL - EQUITY AND LIABILITIES (A1+A2+A3)	13234.88	14504.57	12685.12	14672.53
(j) Tangible fixed assets	518.34	452.71	518.34	1,463.96
(k) Intangible Assets	0.00	0.00	606.75	1,011.25
(l) Capital work-in-progress	0.00	0.49	0.00	0.49
(m) Goodwill (for consolidated result only)	NA	NA	0.07	0.07
(n) Non Current Investment	2554.28	2212.89	1701.32	1890.52
(o) Defered Tax Assets Net	15.58	5.21	15.58	5.21
(p) Long Term loan & Advances	67.69	250.40	67.69	68.79
B1. Sub-total - Non-current assets (j+k+l)	3155.88	2921.70	2909.76	4440.29
(q) Inventories	1303.88	1,499.81	1303.88	1,499.81
(r) Trade receivables	2910.98	3,426.49	2911.04	3,384.41
(s) Cash and cash equivalents	3456.11	3,476.21	3571.39	3,663.84
(t) Short-term loans and advances	2077.61	2,932.70	1822.26	1,546.77
(u) Other current assets	330.41	247.66	166.79	137.41
B2. Sub-total - Current assets (m+n+o+p+q)	10079.00	11582.87	9775.36	10232.24
TOTAL - ASSETS (B1+B2)	13234.88	14504.57	12685.12	14672.53

Handwritten signature in blue ink.





Auditor's Report On Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
Board of Directors of
Alpa Laboratories Limited


We have audited the quarterly financial results of Alpa Laboratories Limited for the quarter ended 31st March, 2017 and financial results for the year ended 31st March, 2017 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting AS 25, prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s).

An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and



C.H. PADLIYA & CO.

CHARTERED ACCOUNTANTS

A. K. PADLIYA M. Com., LL.B., F.C.A.

S. C. PADLIYA M. Com., F.C.A.

VIPUL PADLIYA B. Com., F.C.A.



90, Dawa Bazar, 2nd Floor
13-14 RNT Marg,
Indore - 452 001 (INDIA)
Office : +91 731 2704343
 +91 731 2704133
Residence : +91 731 2515353
 +91 731 2494133

(ii) give a true and fair view of the net profit/~~loss~~ and other financial information for the quarter ended 31st Mach,2017 and for the year ended 31st March,2017

For, C.H Padliya & Co.

Chartered Accountants

ERN 003051C



S.C. Padliya

M.No. 071666

Place: Indore

Date May, 29 2017



Auditor's Report On Quarterly Consolidated Financial Results and Consolidated Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To
Board of Directors of
Alpa Laboratories Limited

We have audited the quarterly Consolidated financial results of Alpa Laboratories Limited for the year to date results for the period ended 31st March, 2017 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These consolidated year to date financial results have been prepared from Consolidated relevant financial statements which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting AS 25, mandated under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s).

An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

We have audited the financial statements of One Subsidiary included in the year to date results, whose Consolidated financial statements reflect total assets of Rs.12685.12 Lacs as at 31.03.2017 (Year to date) as well as the total revenue of Rs. 6568.18 Lacs as at 31.03.2017 (Year to date). The financial statement of subsidiary and other financial information have been audited by us, and our opinion and to the best of our information and according to explanations given to us these consolidated quarterly financial results as well as consolidated year to date results;

(i) include the quarterly financial results and year to date of the following entity

a) Norfolk Mercantile Private Limited (Wholly Owned Subsidiary)



C. H. PADLIYA & CO.

CHARTERED ACCOUNTANTS

A. K. PADLIYA M. Com., LL.B., F.C.A.

S. C. PADLIYA M. Com., F.C.A.

VIPUL PADLIYA B. Com., F.C.A.



90, Dawa Bazar, 2nd Floor
13-14 RNT Marg,
Indore - 452 001 (INDIA)
Office : +91 731 2704343
 +91 731 2704133
Residence : +91 731 2515353
 +91 731 2494133

(ii) have been prepared in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard : and

(iii) give a true and fair view of the consolidated net profit/loss and other financial information for the quarter ended 31st March, 2017 as well as consolidated year to date results for the period ended 31st March, 2017.

For, C.H Padliya & Co.
Chartered Accountants
FRN 003051C

S.C Padliya
M.No. 071666



Place: Indore
Date May, 29 2017